EP300 and hematologic disorder: In this review, we focus on summarizing several representative CREBBP/EP300 BRD inhibitors (CCS1477, CPI-637, and GNE272, etc.)and HAT inhibitors (A485, A-241, and C646, etc.)and their functions in hematological malignancies (Table 4).